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Summary Sodium butyrate has been shown to affect cell proliferation, and, at concentrations above approx-
imately 0.5 mM, to cause cell death in some tumour cell lines. When combined with cytotoxic drugs increase in
chemosensitivity has been observed. We are presently carrying out a study of the combined effects of sodium
butyrate and cytotoxic drugs on cultured cervix tumour cells. To provide a baseline for this study we have
carried out a systematic investigation of the effects of sodium butyrate alone on the growth characteristics of
cervix tumour cells cultured as multicell spheroids. This has shown that concentrations of n-butyrate of
0.005 mM to 0.50 mM decrease cell proliferation without inducing cell death, the effect increasing with
increasing concentration. Butyrate concentrations > 0.50 mM cause cell death after a period of 5 to 15 days
exposure, dependent on concentration. Concentrations of 0.010 mM and above cause fragmentation of, and
increased cell shedding from, multicell spheroids, suggesting an effect on the cell surface. Concentrations of
butyrate > 0.1O mM cause a considerable increase in the synthesis of cytokeratin, as shown by reaction with
cytokeratin antibody. Correlated with this is a marked increase in cell size, concentrations of butyrate of 2.0 or
3.0 mM leading to an approximate doubling of cell diame'ter, followed by cell disintegration. The effects of
butyrate <0.25 mM are readily reversible. At concentrations > 0.25 mM the effects are reversible up to a
limit of about 7 to 20 days depending on concentration, even when cytokeratin synthesis has been induced.
Although early-stage cervical cancer is generally associated
with a good prognosis, disease free survival rates for
advanced disease patients are poor. In vitro studies ofcervical
cancer cells have shown cervical cancer to be relatively
chemoresistant disease (Welander & Parker, 1987). In recur-
rent disease prior radiotherapy or surgery may affect subse-
quent use of chemotherapy by interference with access of the
drug(s) to malignant cells (e.g. Connors, 1984). Possibly
because of these, and other factors, response of cervical
cancer to cytotoxic drugs tends to be short lived and incom-
plete, although cisplatin can provide short term benefit in
some patients (Connors, 1984; Sabir et al., 1989; Alberts et
al., 1991). However, cytotoxic drugs in conjunction with
radiotherapy (Khoury et al., 1991), or combined with
agent(s) which act on cells by a different mechanism, may
prove more beneficial. Of the latter a group of agents which
induce tumour cell maturation or differentiation is currently
of much interest (Cheson et al., 1986) either used alone or in
combination with cytotoxic drugs or irradiation. Sodium n-
butyrate is a member of this group of agents.
The four-carbon fatty acid n-butyrate has been shown Lo
have diverse effects on cell morphology and metabolism in
vitro, to cause inhibition of cell proliferation, and in some
cell lines, and at butyrate concentrations of 0.5 mM and
above, to cause differentiation followed by cell death (see e.g.
Prasad, 1980; Kruh, 1982; Nordenberg et al., 1987). Possibly
combined with the effect of n-butyrate on cell proliferation is
its action in reversibly inducing what has been termed a
'better differentiated phenotype', of increased radiosensitivity
and chemosensitivity (Spremuli & Dexter, 1984). Due to
these properties n-butyrate has been the subject of clinical
investigations in leukaemic patients (Novogrodsky et al.,
1983; Miller et al., 1987). Its effects when combined with
cytotoxic drugs (Wasserman et al., 1989) or irradiation
(Arundel & Leith, 1987; Leith et al., 1986) have also been
investigated.
We are presently carrying out an investigation of the effect
of n-butyrate, when combined with a range of cytotoxic
drugs, on cervix tumour cell lines when cultured as multicell
spheroids. As a necessary preliminary to this study we have
carried out a systematic investigation of the effect of n-
butyrate alone on the growth characteristics of cervix tumour
cells cultured as multicell spheroids. The effect of n-butyrate
concentrations in the range 0.005 to 3 mM has been investi-
gated, and the culture of the cells as multicell spheroids has
allowed measurements over periods of up to 24 days. The
results of this study are presented in this report.
Materials and methods
Cell culture
The cervix tumour cell lines employed in this study were
established in primary culture from cervix biopsy tissue taken
routinely during radiotherapy at Cookridge Hospital (Dyson
et al., 1984a). Six cell lines were used: 754, 612, 995, 090, 329,
708. These were maintained as monolayer cultures from
which multicellular aggregates were obtained as required by
using the method of Sutherland and Durand (1976). Spheroid
cultures were initiated with the same number of spheroids per
flask to allow intercomparison of cell counts during the
period of the experiments. Multicell spheroids were main-
tained in culture as previously described (Boothby et al.,
1989). Excess spheroids were discarded at the time of media
change to maintain cell numbers approximately constant.
The necessary volumes of 50 mM or 500 mM sodium n-
butyrate solution were added to the spheroid suspensions at
the start of the experiment to adjust to the concentrations
shown in the figures, with further additions at media changes
to maintain these concentrations. The butyrate solution was
prepared from n-butyric acid (BDH Limited, Poole, UK) in
Hanks basic salt solution, adjusted to pH 7.2 with NaOH
solution, then sterilised by filtration through an 0.2 gtm Acro-
disc (Gelman Sciences Limited, Northampton, UK).
Spheroid diameter
This was measured by means of a laser diffraction particle
sizer (Malvern Instruments Limited, Malvern, UK) as pre-
viously described (Boothby et al., 1989). The 600 mm range
lens was employed covering the range of diameters of 11.6 to
1128 g1m.
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Cell numbers
Twenty-five ml aliquots were taken from the stirring flasks
and the spheroids and cells collected by centrifugation, the
supernatent was discarded and the pellet suspended in
7.5 mM EDTA to disaggregate the spheroids. After 30 min
incubation at 37°C the EDTA was removed by centrifugation
and the pellet suspended in 1 to 3 ml of phosphate buffered
saline (PBS) and vortexed to complete the disaggregation.
Triplicate counts were made employing a haemacytometer
(improved Neubauer). A record was kept of the volume of
excess spheroids discarded, and aliquots removed for
measurements, and cell counts were corrected for cumulative
volume of spheroids and cells removed.
Cell size
Spheroid aliquots were disaggregated with EDTA as describ-
ed above, then examined under the microscope to ensure a
single cell suspension had been obtained. Cell size was
measured with the laser diffraction particle sizer, with the
100 mm range lens covering the range of diameters of 1.9 to
188gim.
Cytokeratin antibody reaction
The spheroid aliquot was disaggregated as described above.
The final pellet was cooled in ice, then 4 ml of ice-cold 70%
alcohol was added. The fixed cell aliquots were stored at 40C
until processed. The cells were recovered from 70% alcohol
by centrifugation then suspended in 1 ml of PBS plus 0.1%
Tween 20 (Sigma Chemical Company Limited, Poole, UK),
centrifuged again, then the pellet resuspended in 50,l of
PBS/Tween. The antibody used was mouse anti-human cyto-
keratin which reacts with cytokeratin proteins 8 and 18
(CAM 5.2, Becton Dickinson UK Limited, Oxford, UK),
50,ul was added, mixed thoroughly, then incubated for
30 min at 37°C. A further 1 ml of PBS/Tween was then
added, mixed, and the suspension centrifuged and the super-
natent removed. The second antibody was then added, 25;LI
of goat anti-mouse IgG, whole molecule, conjugated with
fluorescein isothiocyanate (FITC) (Sigma F2012, absorbed
human serum proteins), 50gl of PBS/Tween added and mix-
ed and the suspension incubated at 37°C for 30 min. The
suspension was centrifuged and the supernatent removed, the
pellet was suspended in 0.5 ml PBS then 1 ml of propidium
iodide (PI) (Sigma) in PBS added and mixed to give a final
concentration of 25 ytM PI. The suspension was stored over-
night in the refrigerator. The cells were anlaysed with an
Ortho Cytofluorograf Systems 50H flow cytometer equipped
with a Spectra-Physics 2025-03 argon ion laser operating at
the 488 nm line at 400 mW. The green fluorescence intensity,
530 to 565 nm (FITC-cytokeratin) and red fluorescence inten-
sity, >630 nm (PI-DNA) were determined for individual
cells and the data stored in an Ortho 2150 computer module
interfaced to the systems 50H, for later analysis. The mean
value of the green fluorescence intensity distribution was
determined by computer analysis. The extent of the increase
in cytokeratin content due to cell growth in the presence of
n-butyrate was expressed as the ratio of the mean value of
the green fluorescence intensity distribution for butyrate
grown cells to that of the mean value for control cells, for
each concentration of butyrate.
Cell cycle analysis
Spheroid aliquots were removed for analysis at designated
intervals, disaggregated to a single cell suspension as des-
cribed above, then prepared and stained with PI and FITC
for flow cytometric analysis as previously described (Dyson
et al., 1987). Calculation of percent of cells in phases of the
cell cycle was carried out from the DNA content profile by
means of a cell cycle analysis programme developed by Wat-
son et al. (1987).
Cell viability
This was assessed by differential permeability to the stains
ethidium bromide and acridine orange, determined by flow
cytometric measurement (Dyson et al., 1984b).
Results
The majority of the measurements in this investigation were
carried out with two cervix tumour cell lines, 754 and 612.
Both cell lines gave concordant results. Four other cervix cell
lines, 995, 090, 329, and 708 were used in the measurements
of the effect of n-butyrate on cell proliferation rates. These
four cell lines gave an essentially similar response pattern to
n-butyrate as cell lines 754 and 612. The results presented in
this report are those for cervix tumour cell line 754 only to
allow a direct intercomparison of the various cell parameters.
The effect on cell proliferation of continuous exposure to
concentrations of n-butyrate from 0.005 mM to 1.0mM is
shown in Figure 1 for the period 7 to 24 days from initial
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Ki67 antibody reaction
The antibody used was mouse anti-human Ki67 (M722,
Dakopatts Limited, High Wycombe, UK). The processing of
the cells was the same as for the cytokeratin reaction, and the
same second antibody was used. The extent ofthe increase in
the Ki67 reaction was quantitated and expressed in the same
manner as for the cytokeratin reaction.
Figure 1 Reduction in cell proliferation during culture in the
presence of the indicated concentrations of n-butyrate. Cell
number vs days ofexposure to n-butyrate (semi-logarithmic plot).
Culture procedure and method of measurement described in
Materials and methods. (0) control, no n-butyrate; (O) 0.005 mM;
(V) 0.010mM; (V) 0.025mM; (U) 0.050mM; (O) 0.0mM; (A)
0.25 mM; (0) 0.50 mM; (0)1.0mM n-butyrate. Each series of
points is the average of four experiments. Bars show standard
error of the mean (± s.e.). Slopes to points fitted by eye. Cervix
tumour cell line 754.EFFECT OF BUTYRATE ON CERVIX TUMOUR CELLS 805
exposure to n-butyrate. It will be noted that cell numbers for
the control give a straight line on the semi-logarithmic plot
indicating that culture conditions were such that exponential
cell proliferation was maintained. Reductions in cell pro-
liferation may therefore be attributed to the effect of the
n-butyrate and not to nutrient deprivation. At the lowest
concentration of n-butyrate studies, 0.005 mM, there was,
within experimental error, no effect on proliferation rate,
although a trend towards a reduction was observed (Figure
1). At 0.01 mm n-butyrate an approximately 50% reduction
was observed, increase in cell numbers remained exponential,
however, as it did at 0.025 mM n-butyrate (Figure 1). When
the n-butyrate concentration was increased to 0.05 mM and
above the rate of cell proliferation was observed to decrease
further with time ofexposure after a period ofabout 15 to 17
days (Figure 1). At concentrations of 2.0 to 3.0 mM n-
butyrate cell proliferation ceased altogether within a period
of 1 to 3 days, and then cell death ensured over a period of 7
to 20 days (data not shown).
In addition to the effect on cell proliferation a further
effect of n-butyrate on growth of cells as multicell spheroids
was observed when increase in spheroid diameter with time
was measured (Figure 2). Fragmentation of the spheroids
occurred, together with increased cell shedding, this becom-
ing more marked, and occurring at an earlier time, as the
concentration of n-butyrate was increased (Figure 2). The
particle frequency vs spheroid diameter plots displayed by the
particle sizer depict this phenomenon (inset to Figure 2). At
the highest concentrations of n-butyrate, 1.0 to 3.0 mm, no
increase in the diameter of the spheroids was observed and
although some cell proliferation occurred at 1.0 mM (Figure
1), none was apparent at 2.0 and 3.0mM n-butyrate. At 2.0
and 3.0 mM n-butyrate inadequate numbers of cells and cell
aggregates remained for measurement after 13 days (Figure
2), although dying cells and much cell debris were observed
on microscopic examination.
The highest concentrations of n-butyrate (0.25 mM to
3.0 mM) caused considerable increases in cell diameter
(Figure 3). At concentrations of 0.25 and 0.50 mM n-butyrate
the measurements suggest that the cells adapted to the
presence of the n-butyrate, since after reaching a maximum
midway through the measurements the cells had returned to
control value by 24 days (Figure 3). At 1.0 mM n-butyrate
Period of exposure to butyrate (days)
Figure 2 Changes in average spheroid diameter during culture in
the presence of the indicated concentrations of n-butyrate.
Results of a typical experiment. Culture procedure and method of
spheroid measurement described in Materials and methods. (0)
control, no n-butyrate; (V) 0.010 mM; (V) 0.025 mM; (U)
0.050 mM; (O) 0.10 mM; (A) 0.25 mM; (0) 0.50 mM; (0)
1.0 mM; (0) 2.0 mM; (A) 3.0 mM, n-butyrate. Cell line 754.
Inadequate numbers of spheroids for measurement remained
after day 13 at 2.0 mM and 3.0 mM n-butyrate. Inset to Figure 2
frequency of distribution of spheroid diameters at day 20 for
) control; (-- ) 0.1 mM; (------) 1.0mM n-butyrate.
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Figure 3 Changes in average cell diameter during culture in the
presence of the indicated concentrations of n-butyrate. Culture
procedure and method of measurement of cell diameter described
in Materials and methods. (0) control, no n-butyrate; (A)
0.25 mM; (0) 0.50 mM; (0) 1.0mM; (0) 2.0mM; (A) 3.0mM,
n-butyrate. Inadequate numbers of cells at 3.0 mM n-butyrate
remained for measurement after day 21. Each series of points is
the average of four experiments. Bars show±s.e. Cell line 754.
the cells appeared to reach a state of equilibrium with little
change after 7 days (Figure 3). At 2.0 and 3.0 mM n-butyrate
the cells had approximately doubled their diameter by 12 to
17 days; the decrease observed thereafter was most probably
due to death and disintegration of the largest cells (Figure 3).
Essentially the same pattern as for increase in cell size was
observed for increase in cytokeratin content (Figure 4). A
concentration of 0.1 mM n-butyrate produced a trend
towards increased cytokeratin in the latter part of the
measurements, but within experimental error this was not
distinguishable from the control (Figure 4). At days 20 and
24 a significant increase was observed at 0.25 mM n-butyrate
(Figure 4). The small amount of cell proliferation permitted
by 0.50 and 1.0 mM n-butyrate (Figure 1) possibly allowed a
degree of equilibrium to be set up, with cells differentiating
and being lost, then being replaced to some extent by cell
proliferation. This would explain the equilibrium state
suggested by the measurements for these concentrations
(Figure 4).
The reversibility of the action of n-butyrate in inducing
cytokeratin synthesis is depicted in Figure Sa. The period of
exposure to n-butyrate was confined to a period of 7 days,
since beyond that few cells remained viable at n-butyrate
concentrations of 2 or 3 mM. The effect of n-butyrate on the
Ki67 antigen was also measured (Gerdes et al., 1991), during
exposure and following its removal, with the intention of
employing the anticipated decrease in Ki67 levels as a
measure of the reduction in cell proliferation (Gerdes et al.,
1984), for comparison with the increase in cytokeratin levels
employed as a measure of cell differentiation. We found
however, a marked transient increase in the Ki67 antigen,
especially at concentrations of 2.0 and 3.0 mM (Figure Sb).
The Ki67 antigen level was not related to extent of cell
proliferation under these conditions, therefore, but was
apparently accumulated, at least initially, due to the presence
of butyrate (Figure 5b). The decrease in Ki67 observed after
day 4 may have been due to death of those cells with the
highest Ki67 content. On removal of the n-butyrate an in-
crease in the Ki67 antigen was observed for previous expo-
sure to 1.0 to 3.0 mM, with a considerable increase after
exposure to 3.0 mM (Figure Sb). By 10 days from removal of
the n-butyrate Ki67 values had returned nearly to control
levels (Figure 5b), as had values for cytokeratin content
(Figure 5a).
Exposure to n-butyrate did not cause a major accumula-
k
4
/I
I806 J.E.D. DYSON et al.
Period of exposure to butyrate (days)
Figure 4 Changes in cytokeratin content of cells during culture
in the presence of the indicated concentrations of n-butyrate, as
measured by extent of reaction with cytokeratin antibody. Cul-
ture procedure and method of measurement described in Mater-
ials and methods. ()) 0.10 mM; (A) 0.25 mM; (0) 0.50 mM; (0)
1.0 mM; (0) 2.0 mM; (A) 3.0 mM, n-butyrate. Inadequate
numbers of cells at 3.0 mM n-butyrate remained for measurement
after day 17. Each series of points is the average of four experi-
ments. Bars show±s.e. Cell line 754.
2-xpos.d to butyrat;~-butyrate washed out II
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Figure 5 Changes in average cell content of cytokeratin a, and
Ki67 antigen b, during 7 days exposure to n-butyrate and follow-
ing its removal. Culture procedure and methods of measurement
described in Materials and methods. (A) 0.25 mM; (0) 0.50 mM;
(0) 1.0 mM; (0) 2.0 mM; (A) 3.0 mM, n-butyrate. Each series of
points is the average of four experiments. Bars show ± s.e. Cell
line 754.
tion of cells in any phase of the cell cycle, the only phase in
which an appreciable change was observed was G2 where an
increase was apparent between 1 and 2 days after initial
exposure (Figure 6c). Quite marked changes, however, were
apparent on removel of the n-butyrate. There was a con-
siderable decrease in the number of cells in GI as cells moved
out of that phase and into S and G2 phases (Figure 6). This
was especially marked for passage of cells from G1 to S
following exposure to 3.0 mM n-butyrate, and it is interesting
that this cell movement paralleled the considerable increase
in Ki67 antigen following removal of 3.0 mM n-butyrate (cf
Figures 6a, b and 5b).
Discussion
Culture of the cell lines employed in this investigation as
multicell spheroids has allowed observations of the effect of
n-butyrate on the cell growth characteristics of cultured cer-
vix tumour cells over the relatively prolonged period of 24
days. Throughout this period the cells were maintained in
exponential growth (apart from the effect of n-butyrate, cf
Figure 1) by discarding excess cells at media change. This
prolonged period of exposure is important since at concen-
trations of n-butyrate of 0.25 mM and below the effect of
n-butyrate on cell proliferation takes some 7 to 10 days to
become manifest (cf Figures 1 and 2). It is only at concentra-
tions of 0.50 mM and above that n-butyrate causes cell death
in cervix tumour cells, and only at concentrations of 2.0 and
3.0 mM does this appear to be significant. At n-butyrate
concentrations of 0.5 mM and above a proportion of the
cells, increasing with increasing n-butyrate concentration,
synthesise cytokeratin (Figure 4), increase in volume (Figure
3) and eventually disintegrate. On microscopic examination,
or flow cytometric analysis, very few dying or dead cells are
found in the spheroid cultures, but considerable amounts of
cell debris are apparent, principally at 2.0 and 3.0 mM n-
butyrate. At n-butyrate concentrations of 0.25 mM and below
no cell debris is detectable and the effect of n-butyrate
appears to be solely on cell proliferation without causing
differentiation and evenutal death, at least within the 24 day
period of the measurements.
In addition to the reduction in cell proliferation, or possi-
bily related to this reduction, n-butyrate apparently exerts a
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Figure 6 Changes in cell cycle phase fractions during 7 days
exposure of cervix tumour cells to n-butyrate, and following its
removal. Measurements carried out and values calculated as des-
cribed in Materials and methods. (i) 1.0 mM; (0) 2.0 mM; (A)
3.0 mM, n-butyrate. Values shown are the average of three
experiments. Bars show± s.e. Points on extreme left, and horizon-
tal dotted lines, show average control values (±s.e.) during the
course of the measurements. Cell line 754.EFFECT OF BUTYRATE ON CERVIX TUMOUR CELLS 807
surface effect on cells cultured in its presence. As shown in
Figure 2 n-butyrate caused increased cell shedding from the
spheroid surface and spheroids reached an equilibrium
volume with cell loss to the medium at a smaller diameter. At
intermediate concentrations the spheroids fragment after a
period of exposure dependent on the n-butyrate concentra-
tion (Figure 2 and inset to Figure 2). Comparison of Figures
1 and 2 shows that this is not due to cell loss or a change in
cell proliferation. These results seem to be in conflict with
earlier investigations of the effect of n-butyrate which result-
ed in increased cell adhesion (McGarvey et al., 1990) and
increased intercellular adhesion (Frankfurt, 1982). These
investigators employed monolayer cultures in their studies; in
contrast we commenced our measurements with cell aggre-
gates of approximately 120tim diameter, with exposure to
lower concentrations of n-butyrate for a more prolonged
period. However, the fact that increased adhesion has been
observed to be induced by n-butyrate under certain condi-
tions (McGarvey et al., 1990; Frankfurt, 1982) does agree
with our observations insofar as it also suggests an effect of
n-butyrate on the cell surface. How n-butyrate might modify
the cell surface is not at present known, but there is experi-
mental evidence which shows how this could take place. It
has proved possible to modify the cell membrane fatty acid
composition by modification of the culture medium (see e.g.
Spector & Burns, 1987); this also increased cell sensitivity to
adriamycin (Spector & Burns, 1987). Stearic acid, an 18-
carbon fatty acid, has also been shown to inhibit the growth
of human cervical cells (Gleeson et al., 1990). It is, perhaps,
unlikely that a 4-carbon fatty such as n-butyrate would
become directly incorporated into the cell membrane, it is,
however, conceivable that it could modify the action of
certain enzymes involved in membrane synthesis and/or influ-
ence cellular levels of such enzymes. Butyrate has been shown
to modify the activity of various membrane bound enzymes
(e.g. Nordenberg et al., 1987; Wasserman et al., 1989).
Attempts have been made, with limited success, to use
butyrate alone in the treatment of leukaemia (Novogradsky
et al., 1983; Miller et al., 1987). An advantage of butyrate is
that it is a naturally occurring substance with little or no
apparent toxicity (Miller et al., 1987; Daniel et al., 1989). Set
against this, however, is the problem of maintaining effective
plasma concentrations in patients, as the rapid metabolism
and excretion of n-butyrate necessitates the continuous infu-
sion of large volumes of butyrate solution (Miller et al.,
1987). Miller et al. (1987) were able to maintain a butyrate
concentration of about 0.04 to 0.06mM for 10 days. Our
results for cervix tumour cells show that after 24 days
0.05 mM n-butyrate in vitro reduced cell proliferation to 6%
of the control value, and the proliferation rate was still
decreasing at that time (Figure 1). An increase in n-butyrate
concentration to 0.10mm reduced the proliferation to 2.6%
of control at 24 days (Figure 1). Thus it would be advanta-
geous to increase the period of butyrate infusion beyond 10
days and also increase the butyrate plasma concentration if
either of these factors can be achieved. Whether this could be
done without unacceptable damage to actively dividing nor-
mal tissues is not at present known. Possibly a more promis-
ing approach is the combination of butyrate infusion with
radiotherapy or chemotherapy, which we are presently inves-
tigating employing cervix tumour cell lines cultured as multi-
cell spheroids. The effect of the combined treatments on
normal tissue morbidity is largely unknown, but there would
be the advantage in the case of butyrate combined with
radiotherapy that the effect of the combination would largely
be restricted to the volume of the tumour. An alternative
approach both for the butyrate alone or for combination
with other therapy, is the use of derivatives of butyrate which
are less readily metabolised (Planchon et al., 1991).
This work was supported by the Yorkshire Cancer Research Cam-
paign, Harrogate, HG1 5LQ, UK, and by the Cookridge Hospital
Research Fund.
References
ALBERTS, D.S., GARCIA, D. & MASON-LIDDIL, N. (1991). Cisplatin
in advanced cancer of the cervix: an update. Semin. Oncol., 18,
11-24.
ARUNDEL, C.M. & LEITH, J.T. (1987). Effects of nucleoside analogs
and sodium butyrate on recovery from potentially lethal X ray
damage in human colon tumor cells. Int. J. Radiation Oncol. Biol.
Phys., 13, 593-601.
BOOTHBY, C.D., DANIEL, JILL, ADAM, SANDRA & DYSON, J.E.D.
(1989). Use of a laser diffraction particle sizer for the measure-
ment of mean diameter of multicellular tumour spheroids. In
Vitro, 25, 946-950.
CHESON, B.D., JASPERSE, D.M., CHUN, H.G. & FRIEDMAN, M.A.
(1986). Differentiating agents in the treatment of human malig-
nancies. Cancer Treat. Rev., 13, 129-145.
CONNORS, T.A. (1984). The chemotherapy of cervical cancer. In
Cancer of the Uterine Cervix, Biochemical and Clinical Aspects,
McBrien, D.C.H. & Slater, T.F. (eds), pp. 187-190. Academic
Press: London.
DANIEL, P., BRAZIER, M., CERUTTI, J., PIERI, F., TARDIVEL, J.,
DESMET, G., BAILLET, J. & CHANY, C. (1989). Pharmacokinetic
study of butyric acid administered in vivo as sodium and arginine
butyrate salts. Clin. Chim. Acta., 181, 255-264.
DYSON, J.E.D., JOSLIN, C.A.F., QUIRKE, P. & BIRD, C.C. (1984a).
Flow cytofluorometric analysis of serial biopsies of tumours of
the uterine cervix. Eur. J. Cancer Clin. Oncol., 20, 1249-1259.
DYSON, J.E.D., QUIRKE, P., BIRD, C.C., MCLAUGHLIN, J.B. & SUR-
REY, C.R. (1984b). Relationship between cell ploidy and glucocor-
ticoid induced death in human lymphoid cell lines. Br. J. Cancer,
49, 731-738.
DYSON, J.E.D., MCLAUGHLIN, J.B., SURREY, C.R., SIMMONS, D.M.
& DANIEL, J. (1987). Effects of hyperthermia, irradiation and
cytotoxic drugs on fluorescein isothiocyanate staining intensity
for flow cytofluorometry. Cytometry, 8, 26-34.
FRANKFURT, O.S. (1982). Intercellular adhesion in butyrate treated
HeLa S3 cultures. Exp. Cell Res., 139, 257-263.
GERDES, J., LEMKE, H., BAISCH, H., WACKER, H.-H., SCHWAB, U. &
STEIN, H. (1984). Cell cycle analysis of a cell proliferation-
associated human nuclear antigen defined by the monoclonal
antibody Ki-67. J. Immunol., 133, 1710-1715.
GERDES, J., LI, L., SCHLUETER, C., DUCHROW, M., WOHLENBERG,
C., GERLACH, C., STAHMER, I., KLOTH, S., BRANDT, E. & FLAD,
H. (1991). Immunobiochemical and molecular biologic charac-
terization of the cell proliferation associated antigen that is de-
fined by monoclonal antibody Ki67. Am. J. Path., 138, 867-873.
GLEESON, R.P., AYUB, M., WRIGHT, J.T., WOOD, C.B., HABIB, N.A.,
SOUTTER, W.P., SULLIVAN, M.H.F. & WHITE, J.O. (1990). Fatty
acid control of growth of human cervical and endometrial cancer
cells. Br. J. Cancer, 61, 500-503.
KHOURY, G.G., BULMAN, A.S., JOSLIN, C.A.F. & ROTHWELL, R.I.
(1991). Concomitant pelvic irradiation, 5 fluorouracil and mito-
mycin C in the treatment of advanced cervical carcinoma. Br. J.
Radiol., 64, 252-260.
KRUH, J. (1982). Effect of sodium butyrate, a new pharmacological
agent, on cells in culture. Mol. Cell Biochem., 42, 65-82.
LEITH, J.T., HALLOWS, K.T., ARUNDEL, C.M. & BLIVEN, S.F. (1988).
Changes in X-ray sensitivity and glutathione content of human
colon tumor cells after exposure to the differentiating inducing
agent sodium butyrate. Radiat. Res., 114, 579-588.
McGARVEY, T.W., SILBERMAN, S. & PERKSY, B. (1990). The effect
of butyric acid and retinoic acid on invasion and experimental
metastasis of murine melanoma cells. Clin. Expl. Metastasis, 8,
433-448.
MILLER, A.A., KURSCHEL, E., OSIEKA, R. & SCHMIDT, C.G. (1987).
Clinical pharmacology of sodium butyrate in patients with acute
leukaemia. Eur. J. Cancer Clin. Oncol., 23, 1283-1287.
NORDENBERG, J., WASSERMAN, L., PELED, A., MALIK, Z., STEN-
ZEL, K.H. & NOVOGRODSKY, A. (1987). Biochemical and ultra-
structural alterations accompany the anti-proliferative effect of
butyrate on melanoma cells. Br. J. Cancer, 55, 493-497.
NOVOGRODSKY, A., DVIR, A., RAVID, A., SHKOLNIK, T., STENZEL,
K.H., RUBIN, A.L. & ZEIYOR, R. (1983). Effect of polar organic
compounds on leukemic cells: butyrate induced partial remission
of acute myelogenous leukemia in a child. Cancer, 51, 9-14.
PLANCHON, P., RAUX, H., MAGNIEN, V., RONCO, G., VILLA, P.,
CREKIN, M. & BROUTY-BOYE, D. (1991). New stable butyrate
derivates alter proliferation and differentiation in human mam-
mary cells. Int. J. Cancer, 48, 443-449.808 J.E.D. DYSON et al.
PRASAD, K.N. (1980). Butyric acid: a small fatty acid with diverse
biological functions. Life Sci., 27, 1351-1358.
SABIR, A.A., KHOURY, G.G., JOSLIN, C.A.F. & HEAD, C. (1989).
Treatment of recurrent and metastatic carcinoma of cervix with
chemotherapy: a comparison of low dose methotrexate with
adriamycin and methotrexate. Clin. Oncol., 1, 70-74.
SPECTOR, A.A. & BURNS, C.P. (1987). Biological and therapeutic
potential of membrane lipid modification in tumours. Cancer
Res., 47, 4529-4537.
SPREMULI, E.N. & DEXTER, D.L. (1984). Polar solvents: a novel class
of antineoplastic agents. J. Clin. Oncol., 2, 227-235.
SUTHERLAND, R.M. & DURAND, R.E. (1976). Radiation response of
multicellular spheroids - an in vitro tumour model. Curr. Top.
Radiat. Res., 11, 87-139.
WASSERMAN, L., BEERY, E., AVIRAM, R., LEVAVI, H., OVADIA, J.,
NOVOGRODSKY, A. & NORDENBERG, J. (1989). Sodium buty-
rate enhances the activities of membranal enzymes and increases
drug sensitivity in a cell line from ascitic fluid of an ovarian
carcinoma patient. Eur. J. Cancer Clin. Oncol., 25, 1765-1768.
WATSON, J.V., CHAMBERS, S.H. & SMITH, P.J. (1987). A pragmatic
approach to the analysis of DNA histograms with a definable GI
peak. Cytometry, 8, 1-8.
WELANDER, C.E. & PARKER, R.L. Jr (1987). Human tumour clono-
genic assay studies of cervical cancer. In Cervix Cancer, Surwit,
E.A. & Albert, D.S. (eds), pp. 185-197. Martin Nijhoff: Boston,
USA.